Filing Details

Accession Number:
0001104659-24-111566
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-10-25 19:54:22
Reporting Period:
2024-10-23
Accepted Time:
2024-10-25 19:54:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1657312 Verona Pharma Plc VRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1627642 David Zaccardelli 3 More London
Riverside
London X0 SE1 2RE
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2024-10-23 16 $4.38 14,736,536 No 4 S Direct
Ordinary Shares Disposition 2024-10-24 140,000 $4.38 14,596,536 No 4 S Direct
Ordinary Shares Disposition 2024-10-25 4,800 $4.38 14,591,736 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024.
  3. The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.3963 per Ordinary Share, inclusive (or $35.00 to $35.17 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  4. The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.3775 per Ordinary Share, inclusive (or $35.00 to $35.02 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  5. Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 11,766,736 Ordinary Shares underlying 1,470,842 ADSs.